Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Molecular Therapy - Nucleic Acids
Advertisements

Matrix Metalloproteinase-9 Knockout Confers Resistance to Corneal Epithelial Barrier Disruption in Experimental Dry Eye  Stephen C. Pflugfelder, William.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 8, Issue 2, Pages (August 2003)
Molecular Therapy - Nucleic Acids
Volume 19, Issue 2, Pages (February 2011)
Molecular Therapy - Nucleic Acids
Restoration of Corneal Transparency by Mesenchymal Stem Cells
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 18, Issue 10, Pages (October 2010)
Molecular Therapy - Nucleic Acids
Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization  Tae Kwann Park, Si.
Zihua Zeng, Ching-Hsuan Tung, Youli Zu 
Enhancing 1α-Hydroxylase Activity with the 25-Hydroxyvitamin D-1α-Hydroxylase Gene in Cultured Human Keratinocytes and Mouse Skin  Tai C. Chen, Xue Hong.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 9, Pages (September 2010)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 8, Pages (August 2017)
Jan Hoinka, Phuong Dao, Teresa M Przytycka 
Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection  Xinying Tang, Hongbo Zhang,
Control of HCV Replication With iMIRs, a Novel Anti-RNAi Agent
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double- stranded RNA-binding Domain Structure  James C Geoghegan, Brian L Gilmore,
Molecular Therapy - Nucleic Acids
Wei-Yun Lai, Bo-Tsang Huang, Jen-Wei Wang, Pei-Ying Lin, Pan-Chyr Yang 
Molecular Therapy - Nucleic Acids
Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System  Haoran Xin, Mingxing Lei, Zhihui Zhang, Jie Li, Hao Zhang,
Volume 17, Issue 2, Pages (February 2009)
Volume 23, Issue 2, Pages (February 2015)
Molecular Therapy - Nucleic Acids
Jun Asai, Hideya Takenaka, Norito Katoh, Saburo Kishimoto 
Volume 8, Issue 2, Pages (August 2003)
Fiona T van den Berg, John J Rossi, Patrick Arbuthnot, Marc S Weinberg 
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease  Ryan L Boudreau,
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Jia Liu, Thomas Gaj, Mark C Wallen, Carlos F Barbas 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Oncolytics
Xingyu Wang, Can Li, Xiaomeng Gao, Jing Wang, Xingguo Liang 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Arati Sridharan, Chetan Patel, Jit Muthuswamy 
Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Sapana N. Shah, Peijuan.
Presentation transcript:

Molecular Therapy - Nucleic Acids Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal Neovascularization  Yukako Taketani, Tomohiko Usui, Tetsuya Toyono, Nobuyuki Shima, Seiichi Yokoo, Mikiko Kimakura, Satoru Yamagami, Shinichiro Ohno, Risako Onodera, Kohei Tahara, Hirofumi Takeuchi, Masahiko Kuroda  Molecular Therapy - Nucleic Acids  Volume 5, (January 2016) DOI: 10.1038/mtna.2016.1 Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 WST-1 assay of Li-pshRNA. WST-1 assay was performed to confirm cell viability after treatment with Li-pshRNA. There was no significant difference in cell viability among the treatment groups (n = 4, **P < 0.01). ANGPTL2, angiopoietin-like protein 2; Li-pshRNA, proline-modified short hairpin RNA wrapped with liposome. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.1) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Delivery of fluorescence-labeled pshRNA eye drops. (a) Left panel: bare siRNA with fluorescent label; right panel: fluorescence-labeled pshRNA enclosed in the lipid nanoparticle. The pshRNA was distributed only in the superficial layer of the corneal epithelium, while the Li-pshRNA was observed in almost all layers. (b) Delivery of fluorescence-labeled Li-pshRNA drops to mouse eyes. Samples were extracted at 1, 3, and 6 hours after instillation of the eye drops. Left panel: saline as control. Right panel: fluorescence-labeled Li-pshRNA. The Li-pshRNA was distributed to all layers as time advanced. Epi, epithelium; Endo, endothelium of cornea; St, stroma. Li-pshRNA, proline-modified short hairpin RNA wrapped with liposome. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.1) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Reduction of ANGPTL2 mRNA expression in normal cornea after topical administration of ANGPTL2 Li-pshRNA. Reverse transcriptase PCR showed that ANGPTL2 mRNA expression was significantly reduced in the corneal epithelium (a) at 12 and 24 hours (P = 0.049 and <0.001, respectively; n = 7) and in stromal cells (b) at 12 and 24 hours (P = 0.0030 and 0.0021, respectively, n = 7). Expression returned to baseline levels by 72 hours. *P < 0.05, **P < 0.01. ANGPTL2, angiopoietin-like protein 2; Li-pshRNA, proline-modified short hairpin RNA wrapped with liposome. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.1) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Inhibition of ANGPTL2 mRNA by ANGPTL2 Li-pshRNA eye drops after chemical injury. (a) Fluorescence-labeled topical ANGPTL2 Li-pshRNA permeated the entire thickness of the injured cornea at 1 and 3 hours after injury. (b) ANGPTL2 mRNA expression was reduced after topical administration of ANGPTL2 Li-pshRNA eye drops 36 hours after injury (P = 0.017 and 0.032 for saline as control and negative Li-pshRNA, respectively; n = 6). ANGPTL2 mRNA expression was not inhibited by negative Li-pshRNA. *P < 0.05. (c) At 48 hours after injury, levels of ANGPTL2 expression were the same among all three groups. ANGPTL2, angiopoietin-like protein 2; Li-pshRNA, proline-modified short hairpin RNA wrapped with liposome. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.1) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Inhibition of corneal neovascularization by ANGPTL2 Li-psh RNA eye drops. Corneal neovascularization after alkali injury was markedly reduced after 10 days of once-daily treatment with ANGPTL2 Li-pshRNA eye drops (c) compared to eyes treated with control (a) or negative Li-pshRNA (b). Corneas treated with ANGPTL2 Li-pshRNA showed smaller areas of neovascularization (f) compared to control (d) and negative Li-pshRNA (e) corneas. The samples were stained with CD31 to visualize the neovascularization. (g) Corneal neovascularization (CNV) was quantified by area (vascularized area/total cornea area) using image J software. The extent of CNV after ANGPTL2 treatment was significantly smaller compared to the other groups (P < 0.01, n = 9). **P < 0.01. ANGPTL2, angiopoietin-like protein 2; Li-pshRNA, proline-modified short hairpin RNA wrapped with liposome. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.1) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 ANGPTL2 pshRNA platform. PshRNA was synthesized in solid phase as single-stranded RNAs that self-anneal after synthesis into a helical structure containing a single stem loop. Red characters indicated guide sequence, and green characters showed nucleotide cassette sequence of pshRNA. ANGPTL2, angiopoietin-like protein 2; pshRNA, proline-modified short hairpin RNA. A, adenine; C, cytosine; G, guanine; U, uracil; P, proline derivative. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.1) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions